AU2007224213B2 - 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists - Google Patents

8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists Download PDF

Info

Publication number
AU2007224213B2
AU2007224213B2 AU2007224213A AU2007224213A AU2007224213B2 AU 2007224213 B2 AU2007224213 B2 AU 2007224213B2 AU 2007224213 A AU2007224213 A AU 2007224213A AU 2007224213 A AU2007224213 A AU 2007224213A AU 2007224213 B2 AU2007224213 B2 AU 2007224213B2
Authority
AU
Australia
Prior art keywords
endo
oct
ethyl
benzamide
azabicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007224213A
Other languages
English (en)
Other versions
AU2007224213A1 (en
Inventor
Timothy J. Church
Sean Dalziel
John R. Jacobsen
Lan Jiang
Daniel Long
Leticia Preza
Daisuke Roland Saito
Ioanna Stergiades
Priscilla Van Dyke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravance Biopharma R&D IP LLC
Original Assignee
Theravance Biopharma R&D IP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38436795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2007224213(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Biopharma R&D IP LLC filed Critical Theravance Biopharma R&D IP LLC
Publication of AU2007224213A1 publication Critical patent/AU2007224213A1/en
Application granted granted Critical
Publication of AU2007224213B2 publication Critical patent/AU2007224213B2/en
Assigned to THERAVANCE BIOPHARMA R&D IP, LLC reassignment THERAVANCE BIOPHARMA R&D IP, LLC Request for Assignment Assignors: THERAVANCE, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2007224213A 2006-03-01 2007-02-28 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists Active AU2007224213B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77796206P 2006-03-01 2006-03-01
US60/777,962 2006-03-01
US84102806P 2006-08-30 2006-08-30
US60/841,028 2006-08-30
PCT/US2007/005388 WO2007103187A2 (en) 2006-03-01 2007-02-28 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

Publications (2)

Publication Number Publication Date
AU2007224213A1 AU2007224213A1 (en) 2007-09-13
AU2007224213B2 true AU2007224213B2 (en) 2012-06-14

Family

ID=38436795

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007224213A Active AU2007224213B2 (en) 2006-03-01 2007-02-28 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

Country Status (24)

Country Link
US (11) US7622508B2 (enExample)
EP (1) EP2001876B1 (enExample)
JP (2) JP5086280B2 (enExample)
KR (1) KR101376479B1 (enExample)
AR (1) AR059690A1 (enExample)
AT (1) ATE509928T1 (enExample)
AU (1) AU2007224213B2 (enExample)
BR (1) BRPI0708490B8 (enExample)
CA (1) CA2646409C (enExample)
CY (1) CY1111747T1 (enExample)
DK (1) DK2001876T3 (enExample)
HR (1) HRP20110590T1 (enExample)
IL (1) IL193690A (enExample)
MA (1) MA30284B1 (enExample)
MX (1) MX2008011165A (enExample)
MY (1) MY145633A (enExample)
NZ (1) NZ570764A (enExample)
PE (1) PE20071311A1 (enExample)
PL (1) PL2001876T3 (enExample)
PT (1) PT2001876E (enExample)
RU (1) RU2423362C2 (enExample)
SI (1) SI2001876T1 (enExample)
TW (1) TWI379832B (enExample)
WO (1) WO2007103187A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY145633A (en) * 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
TWI415850B (zh) * 2007-07-20 2013-11-21 Theravance Inc 製備ｍｕ類鴉片受體拮抗劑之中間物的方法
TWI423801B (zh) 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
US7947710B2 (en) * 2007-08-27 2011-05-24 Theravance, Inc. Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
EP2195313B1 (en) * 2007-08-27 2014-04-02 Theravance, Inc. Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
ES2390195T3 (es) * 2007-08-27 2012-11-07 Theravance, Inc. Compuestos de amidoalquil-8-azabiciclo(3,2,1)octano, como antagonistas del receptor opioide mu
WO2011035142A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of opioid receptor antagonist for gastrointestinal tract disorders
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
US8759527B2 (en) 2010-08-25 2014-06-24 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
EP2423210A1 (de) 2010-08-25 2012-02-29 Bayer CropScience AG Heteroarylpiperidin- und -piperazinderivate als Fungizide
MX352731B (es) 2010-10-27 2017-12-06 Bayer Ip Gmbh Derivados de heteroarilpiperidina y -piperazina como fungicidas.
JP5703009B2 (ja) * 2010-12-16 2015-04-15 住友精化株式会社 スルホン化合物、スルホン化合物の製造方法、および電気化学デバイス用電解液
KR101848116B1 (ko) 2011-02-01 2018-04-11 바이엘 인텔렉쳐 프로퍼티 게엠베하 살진균제로서의 헤테로아릴 피페리딘 및 헤테로아릴 피페라진 유도체
IN2014CN01862A (enExample) 2011-09-15 2015-05-29 Bayer Ip Gmbh
EP2921492B1 (de) 2011-12-27 2017-09-06 Bayer Intellectual Property GmbH Heteroarylpiperidin- und -heteroarylpiperazinderivate
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
PT3277278T (pt) 2015-04-02 2020-04-16 Theravance Biopharma R&D Ip Llc Forma farmacêutica de combinação de um antagonista do recetor opioide mu e um agente opioide
SG11202007422QA (en) 2018-02-05 2020-09-29 Alkermes Inc Compounds for the treatment of pain
EP4240740A4 (en) * 2020-11-06 2024-12-11 Actinogen Medical Limited PROCESS FOR PREPARING HETEROCYCLIC METHANONE COMPOUNDS AND AZABICYCLO INTERMEDIATES THEREOF

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181447A1 (en) * 2001-02-22 2003-09-25 Boyd Robert E. 3-(Diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives
WO2004089908A2 (en) * 2003-04-14 2004-10-21 Pfizer Products Inc. 3-azabicyclo[3.2.1]octane derivatives
WO2004089909A1 (en) * 2003-04-14 2004-10-21 Pfizer Products Inc. 2-azabicyclo[3.3.1]nonane derivatives as opioid receptor antagonists

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1067824B (de) * 1954-10-20 1959-10-29 Sandoz Ag Verfahren zur Herstellung saeureamidartiger Tropanabkoemmlinge
US5159081A (en) 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
UA58476C2 (uk) * 1997-10-09 2003-08-15 Санофі-Сентелябо Похідні 8-азабіцикло[3.2.1]октан-3-метанаміну, фармацевтична композиція та лікарський засіб
US6900228B1 (en) 1998-03-10 2005-05-31 Research Triangle Institute Opiate compounds, methods of making and methods of use
GB9810671D0 (en) 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
TWI244481B (en) 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
KR20030009376A (ko) 2000-03-03 2003-01-29 오르토-맥네일 파마슈티칼, 인코퍼레이티드 3-(디아릴메틸렌)-8-아자비사이클로[3.2.1]옥탄 유도체
US20020025948A1 (en) 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
JP4009251B2 (ja) 2001-10-09 2007-11-14 杏林製薬株式会社 新規な４−（２−フロイル）アミノピペリジン、その合成中間体、その製造方法および医薬としてのその用途
GEP20084300B (en) 2001-10-22 2008-02-11 Pfizer Prod Inc 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
US7381721B2 (en) 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
US20040204453A1 (en) 2003-04-14 2004-10-14 Pfizer Inc 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors
CA2522199A1 (en) 2003-04-15 2004-10-28 Pfizer Products Inc. 3-benzhydrylidene-8-aza-bicyclo¬3.2.1|octane derivatives with opioid receptor activity
US6992090B2 (en) 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
EP1737853A1 (en) 2004-02-03 2007-01-03 Janssen Pharmaceutica N.V. 3-(diheteroarylmethylene)-8-azabicyclo¬3.2.1|octane and 3-((aryl)(heteroaryl)methylene)-8-azabicyclo¬3.2.1|octane derivatives
US7087749B2 (en) 2004-03-11 2006-08-08 Adolor Corporation Substituted piperidine compounds and methods of their use
US7538110B2 (en) 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
MX2009004965A (es) 2006-11-07 2009-06-05 Nektar Therapeutics Al Corp Formas de dosificacion y co-administracion de un agonista de opioides y un antagonista de opioides.
TWI409067B (zh) 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
TWI415850B (zh) * 2007-07-20 2013-11-21 Theravance Inc 製備ｍｕ類鴉片受體拮抗劑之中間物的方法
EP2195313B1 (en) * 2007-08-27 2014-04-02 Theravance, Inc. Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
US7947710B2 (en) * 2007-08-27 2011-05-24 Theravance, Inc. Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI423801B (zh) * 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
ES2390195T3 (es) 2007-08-27 2012-11-07 Theravance, Inc. Compuestos de amidoalquil-8-azabiciclo(3,2,1)octano, como antagonistas del receptor opioide mu

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181447A1 (en) * 2001-02-22 2003-09-25 Boyd Robert E. 3-(Diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives
WO2004089908A2 (en) * 2003-04-14 2004-10-21 Pfizer Products Inc. 3-azabicyclo[3.2.1]octane derivatives
WO2004089909A1 (en) * 2003-04-14 2004-10-21 Pfizer Products Inc. 2-azabicyclo[3.3.1]nonane derivatives as opioid receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorganic and Medicinal Chemistry Letters, vol. 13, p.1817-20 (2003) *

Also Published As

Publication number Publication date
US20190119267A1 (en) 2019-04-25
WO2007103187A2 (en) 2007-09-13
PE20071311A1 (es) 2007-12-29
RU2008138875A (ru) 2010-04-10
US8664242B2 (en) 2014-03-04
WO2007103187A3 (en) 2007-11-01
US20170349578A1 (en) 2017-12-07
US20210024515A1 (en) 2021-01-28
US8263618B2 (en) 2012-09-11
JP2012211193A (ja) 2012-11-01
ATE509928T1 (de) 2011-06-15
US20160176863A1 (en) 2016-06-23
US10377751B2 (en) 2019-08-13
US10081626B2 (en) 2018-09-25
TW200800981A (en) 2008-01-01
HRP20110590T1 (hr) 2011-09-30
US20130158060A1 (en) 2013-06-20
SI2001876T1 (sl) 2011-09-30
US8927573B2 (en) 2015-01-06
BRPI0708490B8 (pt) 2021-05-25
IL193690A0 (en) 2009-08-03
TWI379832B (en) 2012-12-21
US20140288112A1 (en) 2014-09-25
RU2423362C2 (ru) 2011-07-10
EP2001876B1 (en) 2011-05-18
US20230183232A1 (en) 2023-06-15
US11548887B2 (en) 2023-01-10
US20100035921A1 (en) 2010-02-11
MX2008011165A (es) 2008-09-15
CA2646409A1 (en) 2007-09-13
US20150291579A1 (en) 2015-10-15
BRPI0708490A2 (pt) 2011-05-31
US10745394B2 (en) 2020-08-18
AU2007224213A1 (en) 2007-09-13
KR101376479B1 (ko) 2014-03-27
JP2009528371A (ja) 2009-08-06
US7622508B2 (en) 2009-11-24
PL2001876T3 (pl) 2011-10-31
AR059690A1 (es) 2008-04-23
US20190308966A1 (en) 2019-10-10
KR20080100282A (ko) 2008-11-14
PT2001876E (pt) 2011-08-18
IL193690A (en) 2013-02-28
MA30284B1 (fr) 2009-03-02
BRPI0708490B1 (pt) 2019-07-30
US20070219278A1 (en) 2007-09-20
US9663509B2 (en) 2017-05-30
DK2001876T3 (da) 2011-08-29
MY145633A (en) 2012-03-15
CY1111747T1 (el) 2015-10-07
HK1125935A1 (en) 2009-08-21
NZ570764A (en) 2011-08-26
JP5086280B2 (ja) 2012-11-28
US9206172B2 (en) 2015-12-08
EP2001876A2 (en) 2008-12-17
CA2646409C (en) 2015-11-10

Similar Documents

Publication Publication Date Title
US20230183232A1 (en) 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
EP2195314B1 (en) Disubstituted alkyl-8-azabicyclo [3.2.1.]octane compounds as mu opioid receptor antagonists
AU2008293974B9 (en) 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists
EP2185553B1 (en) Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
ES2366058T3 (es) Compuestos de 8-azabiciclo[3.2.1]octano como antagonistas de los receptores opioides mu.
HK1125935B (en) 8-azabicyclo [3.2.1] octane compounds as mu opioid receptor antagonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: THERAVANCE BIOPHARMA R&D IP, LLC

Free format text: FORMER OWNER WAS: THERAVANCE, INC.